Delcath Systems, Inc. is an interventional oncology company based in Queensbury, New York, specializing in the treatment of primary and metastatic liver cancers. Founded in 1987 or 1988, the company develops proprietary medical devices and pharmaceutical products that allow for targeted delivery of high-dose chemotherapy directly to the liver, minimizing systemic exposure and side effects.

The flagship product, the HEPZATO KIT, combines melphalan hydrochloride for injection with a hepatic delivery system, primarily used for treating unresectable hepatic-dominant metastatic uveal melanoma and other liver cancers. In Europe, it is also marketed as the CHEMOSAT Hepatic Delivery System. Delcath's technology, known as Percutaneous Hepatic Perfusion (PHP), is a minimally invasive procedure that enhances drug concentration at liver tumors while reducing systemic toxicity. The company has received FDA approval and European marketing authorization, and it collaborates with institutions like the National Cancer Institute on clinical trials. Delcath serves hospitals and medical centers in the U.S. and Europe that focus on oncology, employing around 96 people.